ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

@article{Zammarchi2018ADCT402AP,
  title={ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.},
  author={Francesca Zammarchi and Simon Corbett and Lauren N Adams and Peter Tyrer and Konstantinos Kiakos and Narinder Janghra and Teresa Marafioti and Charles E Britten and Carin E. G. Havenith and Simon Chivers and François D'Hooge and David G. Williams and Arnaud Tiberghien and Philip W. Howard and John A. Hartley and Patrick H.C. van Berkel},
  journal={Blood},
  year={2018},
  volume={131 10},
  pages={1094-1105}
}
Human CD19 antigen is a 95-kDa type I membrane glycoprotein in the immunoglobulin superfamily whose expression is limited to the various stages of B-cell development and differentiation and is maintained in the majority of B-cell malignancies, including leukemias and non-Hodgkin lymphomas of B-cell origin. Coupled with its differential and favorable… CONTINUE READING